The Clinical Trial for Evaluation of Efficacy and Safety of rhEGF (Recombinant Human Epidermal Growth Factor) in Diabetic Foot Ulcer Patients With Uncontrolled Diabetes Mellitus.

Trial Profile

The Clinical Trial for Evaluation of Efficacy and Safety of rhEGF (Recombinant Human Epidermal Growth Factor) in Diabetic Foot Ulcer Patients With Uncontrolled Diabetes Mellitus.

Completed
Phase of Trial: Phase III

Latest Information Update: 03 Sep 2014

At a glance

  • Drugs Nepidermin (Primary)
  • Indications Diabetic foot ulcer
  • Focus Therapeutic Use
  • Sponsors Daewoong Pharmaceutical
  • Most Recent Events

    • 03 Sep 2014 Results published in a Daewoong Pharmaceutical media release.
    • 01 Aug 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 12 Jul 2012 Planned patient number is 176 according to ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top